Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0IMAKZ
ADC Name
Mecbotamab vedotin
Synonyms
BA 3011; HTBA-3011; CAB-Axl antibody-drug conjugates; CAB-AXL-ADC; BA3011; HTBA3011
   Click to Show/Hide
Organization
BioAtla, Inc.
Drug Status
Phase 2
Indication
In total 8 Indication(s)
Ewing sarcoma [ICD11:2B52]
Phase 2
Liposarcoma [ICD11:2B59]
Phase 2
Melanoma [ICD11:2C30]
Phase 2
Non-small cell lung cancer [ICD11:2C25]
Phase 2
Ovarian cancer [ICD11:2C73]
Phase 2
Pancreatic cancer [ICD11:2C10]
Phase 2
Soft tissue sarcoma [ICD11:2B5F]
Phase 2
Synovial sarcoma [ICD11:2B5A]
Phase 2
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Mecbotamab
  Antibody Info 
Antigen Name
Tyrosine-protein kinase receptor UFO (AXL)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
Vedotin
Puchem SID
472420565 , 445594980 , 476000779
Drugbank ID
DB17442
ChEBI ID
CHEMBL5095312
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT04681131
Phase 2
A phase 2 study of BA3011 alone and in combination with PD-1 inhibitor in adult patients with metastatic non-small cell lung cancer (NSCLC) who had prior disease progression on a PD-1/L-1 inhibitor.
Undisclosed  NCT03425279
Phase 1
A phase 1/ 2 safety and efficacy dose escalation/dose expansion study of a CAB-AXL-ADC, alone and in combination with a PD-1 inhibitor in adult patients with advanced solid tumors (phase 1) and adult and adolescent patients with advanced, refractory sarcoma (phase 2).

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT04681131  Clinical Status Phase 2
Clinical Description A phase 2 study of BA3011 alone and in combination with PD-1 inhibitor in adult patients with metastatic non-small cell lung cancer (NSCLC) who had prior disease progression on a PD-1/L-1 inhibitor.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT03425279  Clinical Status Phase 1
Clinical Description A phase 1/ 2 safety and efficacy dose escalation/dose expansion study of a CAB-AXL-ADC, alone and in combination with a PD-1 inhibitor in adult patients with advanced solid tumors (phase 1) and adult and adolescent patients with advanced, refractory sarcoma (phase 2).
References
Ref 1 A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, NCT04681131
Ref 2 A Phase 1/ 2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-AXL-ADC, Alone and in Combination With a PD-1 Inhibitor in Adult Patients With Advanced Solid Tumors (Phase 1) and Adult and Adolescent Patients With Advanced, Refractory Sarcoma (Phase 2), NCT03425279

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.